Join Growin Stock Community!

Briacell therapeutics corp.BCTX.US Overview

US StockHealthcare
(No presentation for BCTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCTX AI Insights

BCTX Overall Performance

BCTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCTX Recent Performance

-4.58%

Briacell therapeutics corp.

0.05%

Avg of Sector

-0.31%

S&P500

BCTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCTX Key Information

BCTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCTX Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Price of BCTX

BCTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.91
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.91
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BCTX's latest earnings report released?

    The most recent financial report for Briacell therapeutics corp. (BCTX) covers the period of 2026Q1 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCTX's short-term business performance and financial health. For the latest updates on BCTX's earnings releases, visit this page regularly.

  • How much cash does BCTX have?

    At the end of the period, Briacell therapeutics corp. (BCTX) held Total Cash and Cash Equivalents of 2.71M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BCTX's EPS continuing to grow?

    According to the past four quarterly reports, Briacell therapeutics corp. (BCTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -4.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCTX?

    Briacell therapeutics corp. (BCTX)'s Free Cash Flow (FCF) for the period is -7.7M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 10.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BCTX?

    The latest valuation data shows Briacell therapeutics corp. (BCTX) has a Price-To-Earnings (PE) ratio of -0.67 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.